Avenue Biosciences
About Avenue Biosciences
Avenue Biosciences utilizes a proprietary protein engineering platform that combines high-throughput chemistry and machine learning to enhance protein expression yields by up to 500%. This technology addresses the challenge of producing difficult-to-express proteins, facilitating the development of mRNA therapies and biologics.
```xml <problem> Producing certain therapeutic proteins and biologics at high yields can be challenging, hindering the development of mRNA therapies, vaccines, and other protein-based drugs. Traditional protein expression methods often struggle with difficult-to-express proteins, leading to bottlenecks in research and manufacturing. </problem> <solution> Avenue Biosciences offers a protein engineering platform that leverages high-throughput chemistry and machine learning to optimize protein expression. The platform analyzes thousands of N-terminal signal peptides to identify candidates that significantly improve protein yield, in some cases by up to 500%. This technology is compatible with various mammalian protein production systems, including mRNA therapies, synthetic proteins, and multi-chain proteins like monoclonal antibodies. By enhancing protein production, Avenue Biosciences aims to accelerate therapeutic development and reduce time-to-market for novel biologics. </solution> <features> - High-throughput screening of naturally occurring and genetically engineered signal peptides - Machine learning-driven analysis to predict and optimize protein expression - Demonstrated yield improvements of up to 500% in external validations - Compatible with diverse protein production systems, including mammalian cell lines - Enables production of difficult-to-express proteins that hinder therapeutic development - Facilitates single-chain and multi-chain protein expression optimization </features> <target_audience> The primary target audience includes biopharmaceutical companies, biotechnology firms, and research institutions involved in developing protein biologics, mRNA therapies, vaccines, and other protein-based therapeutics. </target_audience> ```
What does Avenue Biosciences do?
Avenue Biosciences utilizes a proprietary protein engineering platform that combines high-throughput chemistry and machine learning to enhance protein expression yields by up to 500%. This technology addresses the challenge of producing difficult-to-express proteins, facilitating the development of mRNA therapies and biologics.
Where is Avenue Biosciences located?
Avenue Biosciences is based in Palo Alto, United States.
When was Avenue Biosciences founded?
Avenue Biosciences was founded in 2023.
How much funding has Avenue Biosciences raised?
Avenue Biosciences has raised 2500000.
- Location
- Palo Alto, United States
- Founded
- 2023
- Funding
- 2500000
- Employees
- 10 employees
- Major Investors
- Voima Ventures